MedElevator Войти в исследования
← Поиск публикаций

DOI 10.19746/j.cnki.issn.1009-2137.2026.01.016

Медицинская библиотека · Zhongguo shi yan xue ye xue za zhi · 2026

[Clinical Study on the Transition of First-Line Bortezomib Intole- rance to Carfilzomib in the Treatment of Multiple Myeloma].

Yao Ying, Shi Xiao-Lan, Wang Pan-Feng, Xu Yun, Yan Shuang, Meng Jia-Jia, Jiang Yu-Xin, Wang Peng, Wang Jing, Ma Xiao, Fu Cheng-Cheng, Wu De-Pei, Yan Ling-Zhi

Аннотация на английскомСтатьяПеревод в очереди

Аннотация

OBJECTIVE

To evaluate the feasibility of in-class transition(iCT) first-line bortezomib intolerance to carfilzomib in the treatment of patients with multiple myeloma(MM).

METHODS

It was retrospectively collected that the clinical data of MM patients who transitioned to carfilzomib due to intolerance, such as ≥grade 1 painful peripheral neuropathy (PN), during the treatment with first-line bortezomib-based triple regimens in the First Affiliated Hospital of Soochow University and Soochow Hopes Hematology Hospital from March 2023 to January 2025, and their safety and efficacy were analyzed.

RESULTS

A total of 23 MM patients were included. The cohort had a median age of 63 (46-75) years. The median treatment cycle of bortezomib before iCT was 4 (1-6). Among the causes of intolerance, there were 22 cases of PN and 1 case of diarrhea. With a median follow-up of 10(2-23) months, at 1 month, 2 months and 4 months, 1/22, 3/22, and 12/20 of patients reduced by one grade in PN after transition. At 4 months after transition, all patients' peripheral neuropathic pain symptoms had disappeared. After 2 months of transition, there was a significant decrease in overall neuropathy limitations scale (ONLS) and total neuropathy score (TNS) scores compared to baseline (P <0.001). After carfilzomib treatment, the decrease in grade≥3 neutropenia from 21.7% to 17.4%(P=0.021).The additional non-hematological toxicity was transient, with grade 1-2 hypertension(47.8%) and QTcF prolongation(13.0%). In terms of efficacy analysis, the conversion rate of ≥CR increased from 30.4% to 69.5% (P=0.047), and the sCR rate and mininal residual disease (MRD) negative conversion rate both increased from 30.4% to 65.2% (P=0.026).

CONCLUSION

The transition of first-line bortezomib intolerance to carfilzomib can significantly improve symptoms such as PN and deepen remission.

Для цитирования: Yao Ying, Shi Xiao-Lan, Wang Pan-Feng, Xu Yun, Yan Shuang, Meng Jia-Jia, Jiang Yu-Xin, Wang Peng, Wang Jing, Ma Xiao, Fu Cheng-Cheng, Wu De-Pei, Yan Ling-Zhi. [Clinical Study on the Transition of First-Line Bortezomib Intole- rance to Carfilzomib in the Treatment of Multiple Myeloma].. Zhongguo shi yan xue ye xue za zhi. 2026. DOI: 10.19746/j.cnki.issn.1009-2137.2026.01.016.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.